• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PROTAC-DB:一个 PROTAC 数据库。

PROTAC-DB: an online database of PROTACs.

机构信息

Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, Zhejiang, China.

State Key Lab of CAD&CG, Zhejiang University, Hangzhou 310058, Zhejiang, China.

出版信息

Nucleic Acids Res. 2021 Jan 8;49(D1):D1381-D1387. doi: 10.1093/nar/gkaa807.

DOI:10.1093/nar/gkaa807
PMID:33010159
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7778940/
Abstract

Proteolysis-targeting chimeras (PROTACs), which selectively degrade targeted proteins by the ubiquitin-proteasome system, have emerged as a novel therapeutic technology with potential advantages over traditional inhibition strategies. In the past few years, this technology has achieved substantial progress and two PROTACs have been advanced into phase I clinical trials. However, this technology is still maturing and the design of PROTACs remains a great challenge. In order to promote the rational design of PROTACs, we present PROTAC-DB, a web-based open-access database that integrates structural information and experimental data of PROTACs. Currently, PROTAC-DB consists of 1662 PROTACs, 202 warheads (small molecules that target the proteins of interest), 65 E3 ligands (small molecules capable of recruiting E3 ligases) and 806 linkers, as well as their chemical structures, biological activities, and physicochemical properties. Except the biological activities of warheads and E3 ligands, PROTAC-DB also provides the degradation capacities, binding affinities and cellular activities for PROTACs. PROTAC-DB can be queried with two general searching approaches: text-based (target name, compound name or ID) and structure-based. In addition, for the convenience of users, a filtering tool for the searching results based on the physicochemical properties of compounds is also offered. PROTAC-DB is freely accessible at http://cadd.zju.edu.cn/protacdb/.

摘要

蛋白水解靶向嵌合体(PROTACs)通过泛素-蛋白酶体系统选择性降解靶蛋白,作为一种新型治疗技术,具有优于传统抑制策略的潜在优势。在过去的几年中,该技术取得了实质性的进展,有两种 PROTACs 已进入 I 期临床试验。然而,该技术仍在成熟过程中,PROTACs 的设计仍然是一个巨大的挑战。为了促进 PROTACs 的合理设计,我们提出了 PROTAC-DB,这是一个基于网络的开放获取数据库,集成了 PROTACs 的结构信息和实验数据。目前,PROTAC-DB 包含 1662 种 PROTACs、202 种弹头(靶向感兴趣的蛋白质的小分子)、65 种 E3 配体(能够招募 E3 连接酶的小分子)和 806 种连接子,以及它们的化学结构、生物活性和物理化学性质。除了弹头和 E3 配体的生物活性外,PROTAC-DB 还提供了 PROTACs 的降解能力、结合亲和力和细胞活性。PROTAC-DB 可以通过两种通用的搜索方法进行查询:基于文本的(目标名称、化合物名称或 ID)和基于结构的。此外,为了方便用户,还提供了一种基于化合物物理化学性质的搜索结果过滤工具。PROTAC-DB 可在 http://cadd.zju.edu.cn/protacdb/ 免费获取。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0756/7778940/4952c1a33c6b/gkaa807fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0756/7778940/985c952145ff/gkaa807gra1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0756/7778940/6d8ad1f1afa3/gkaa807fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0756/7778940/61f255e16a48/gkaa807fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0756/7778940/d1a3de38d926/gkaa807fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0756/7778940/4952c1a33c6b/gkaa807fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0756/7778940/985c952145ff/gkaa807gra1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0756/7778940/6d8ad1f1afa3/gkaa807fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0756/7778940/61f255e16a48/gkaa807fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0756/7778940/d1a3de38d926/gkaa807fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0756/7778940/4952c1a33c6b/gkaa807fig4.jpg

相似文献

1
PROTAC-DB: an online database of PROTACs.PROTAC-DB:一个 PROTAC 数据库。
Nucleic Acids Res. 2021 Jan 8;49(D1):D1381-D1387. doi: 10.1093/nar/gkaa807.
2
PROTAC-DB 2.0: an updated database of PROTACs.PROTAC-DB 2.0:一个更新的 PROTAC 数据库。
Nucleic Acids Res. 2023 Jan 6;51(D1):D1367-D1372. doi: 10.1093/nar/gkac946.
3
PROTAC-DB 3.0: an updated database of PROTACs with extended pharmacokinetic parameters.PROTAC-DB 3.0:一个具有扩展药代动力学参数的PROTACs更新数据库。
Nucleic Acids Res. 2025 Jan 6;53(D1):D1510-D1515. doi: 10.1093/nar/gkae768.
4
Small-molecule PROTACs: novel agents for cancer therapy.小分子 PROTACs:癌症治疗的新型药物。
Future Med Chem. 2020 May;12(10):915-938. doi: 10.4155/fmc-2019-0340. Epub 2020 Apr 9.
5
Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.从具有混杂弹头的选择性降解中吸取 PROTAC 设计的经验教训。
Cell Chem Biol. 2018 Jan 18;25(1):78-87.e5. doi: 10.1016/j.chembiol.2017.09.010. Epub 2017 Nov 9.
6
Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs.小分子 PROTACs:一种新兴且有前景的靶向治疗药物开发方法。
EBioMedicine. 2018 Oct;36:553-562. doi: 10.1016/j.ebiom.2018.09.005. Epub 2018 Sep 14.
7
PROTACs: New method to degrade transcription regulating proteins.PROTACs:降解转录调控蛋白的新方法。
Eur J Med Chem. 2020 Dec 1;207:112698. doi: 10.1016/j.ejmech.2020.112698. Epub 2020 Aug 15.
8
E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.E3 连接酶配体用于 PROTACs:它们是如何被发现的,以及如何发现新的配体。
SLAS Discov. 2021 Apr;26(4):484-502. doi: 10.1177/2472555220965528. Epub 2020 Nov 3.
9
Small-Molecule Degraders beyond PROTACs-Challenges and Opportunities.超越PROTAC的小分子降解剂——挑战与机遇
SLAS Discov. 2021 Apr;26(4):524-533. doi: 10.1177/2472555221991104. Epub 2021 Feb 25.
10
PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.PROteolysis TArgeting Chimeras (PROTACs) 作为新兴的抗癌治疗药物。
Oncogene. 2020 Jun;39(26):4909-4924. doi: 10.1038/s41388-020-1336-y. Epub 2020 May 31.

引用本文的文献

1
In-cell proximity target validation methods for heterobifunctional molecules with CRBN- or VHL-binder using AirID.使用AirID对具有CRBN或VHL结合剂的异双功能分子进行细胞内邻近靶点验证的方法
Commun Biol. 2025 Aug 30;8(1):1323. doi: 10.1038/s42003-025-08761-x.
2
PROTAC technology for prostate cancer treatment.用于前列腺癌治疗的PROTAC技术。
Acta Mater Med. 2025 Jan 7;4(1):99-121. doi: 10.15212/amm-2024-0075. Epub 2025 Jan 30.
3
Linker Methylation as a Strategy to Enhance PROTAC Oral Bioavailability: Insights from Molecular Properties and Conformational Analysis.

本文引用的文献

1
Targeted degraders clear first safety hurdles.靶向降解剂跨越了首个安全障碍。
Nat Rev Drug Discov. 2020 Jul;19(7):435. doi: 10.1038/d41573-020-00109-w.
2
Developing degraders: principles and perspectives on design and chemical space.开发降解剂:设计与化学空间的原理及展望
Medchemcomm. 2019 Aug 12;10(10):1755-1764. doi: 10.1039/c9md00272c. eCollection 2019 Oct 1.
3
A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo.一种强效且选择性的 STAT3 小分子降解剂在体内实现完全肿瘤消退。
连接子甲基化作为提高PROTAC口服生物利用度的策略:来自分子性质和构象分析的见解
J Med Chem. 2025 Aug 14;68(15):16666-16677. doi: 10.1021/acs.jmedchem.5c01497. Epub 2025 Jul 31.
4
Advancing Design Strategy of PROTACs for Cancer Therapy.用于癌症治疗的PROTACs的先进设计策略
MedComm (2020). 2025 Jun 25;6(7):e70258. doi: 10.1002/mco2.70258. eCollection 2025 Jul.
5
Gene regulation technologies for gene and cell therapy.用于基因和细胞治疗的基因调控技术。
Mol Ther. 2025 May 7;33(5):2104-2122. doi: 10.1016/j.ymthe.2025.04.004. Epub 2025 Apr 6.
6
Exploring chemical space for "druglike" small molecules in the age of AI.在人工智能时代探索“类药物”小分子的化学空间。
Front Mol Biosci. 2025 Mar 17;12:1553667. doi: 10.3389/fmolb.2025.1553667. eCollection 2025.
7
Targeting Tau Protein with Proximity Inducing Modulators: A New Frontier to Combat Tauopathies.用邻近诱导调节剂靶向tau蛋白:对抗tau蛋白病的新前沿。
ACS Pharmacol Transl Sci. 2025 Feb 10;8(3):654-672. doi: 10.1021/acsptsci.4c00733. eCollection 2025 Mar 14.
8
MEGA PROTAC, MEGA DOCK-based PROTAC mediated ternary complex formation pipeline with sequential filtering and rank aggregation.基于MEGA DOCK的MEGA PROTAC介导的三元复合物形成流程,具有顺序过滤和排名聚合。
Sci Rep. 2025 Feb 14;15(1):5545. doi: 10.1038/s41598-024-83558-2.
9
ET-PROTACs: modeling ternary complex interactions using cross-modal learning and ternary attention for accurate PROTAC-induced degradation prediction.ET-PROTACs:使用跨模态学习和三元注意力对三元复合物相互作用进行建模,以实现准确的PROTAC诱导降解预测。
Brief Bioinform. 2024 Nov 22;26(1). doi: 10.1093/bib/bbae654.
10
Impact of Linker Composition on VHL PROTAC Cell Permeability.连接子组成对VHL PROTAC细胞渗透性的影响。
J Med Chem. 2025 Jan 9;68(1):638-657. doi: 10.1021/acs.jmedchem.4c02492. Epub 2024 Dec 18.
Cancer Cell. 2019 Nov 11;36(5):498-511.e17. doi: 10.1016/j.ccell.2019.10.002.
4
The IUPHAR/BPS Guide to PHARMACOLOGY in 2020: extending immunopharmacology content and introducing the IUPHAR/MMV Guide to MALARIA PHARMACOLOGY.2020 年国际药理学联合会/英国药理学学会药物学指南:扩充免疫药理学内容并推出国际药理学联合会/MMV 疟疾药物学指南。
Nucleic Acids Res. 2020 Jan 8;48(D1):D1006-D1021. doi: 10.1093/nar/gkz951.
5
Targeted protein degradation: expanding the toolbox.靶向蛋白降解:拓展工具盒。
Nat Rev Drug Discov. 2019 Dec;18(12):949-963. doi: 10.1038/s41573-019-0047-y. Epub 2019 Oct 30.
6
Development of targeted protein degradation therapeutics.靶向蛋白降解治疗药物的研发。
Nat Chem Biol. 2019 Oct;15(10):937-944. doi: 10.1038/s41589-019-0362-y. Epub 2019 Sep 16.
7
BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design.基于结构的 PROTAC 设计揭示 BAF 复合物在癌症中的脆弱性。
Nat Chem Biol. 2019 Jul;15(7):672-680. doi: 10.1038/s41589-019-0294-6. Epub 2019 Jun 10.
8
Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges.“超越五规则”化学空间中的蛋白酶靶向嵌合体(PROTACs):近期进展与未来挑战
Bioorg Med Chem Lett. 2019 Jul 1;29(13):1555-1564. doi: 10.1016/j.bmcl.2019.04.030. Epub 2019 Apr 20.
9
Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6.开发细胞周期蛋白依赖性激酶 4 和 6 的双重和选择性降解剂。
Angew Chem Int Ed Engl. 2019 May 6;58(19):6321-6326. doi: 10.1002/anie.201901336. Epub 2019 Mar 29.
10
Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer.发现 ARD-69 是一种高效的蛋白酶靶向嵌合体(PROTAC)降解剂,可用于治疗前列腺癌的雄激素受体(AR)。
J Med Chem. 2019 Jan 24;62(2):941-964. doi: 10.1021/acs.jmedchem.8b01631. Epub 2019 Jan 10.